Searchable abstracts of presentations at key conferences on calcified tissues
Previous issue | Volume 5 | ECTS2016 | Next issue

43rd Annual European Calcified Tissue Society Congress

Rome, Italy
14 May 2016 - 17 May 2016

Card image cap

Oral Communications

Clinical trials and osteoporosis treatment

ba0005oc1.1 | Clinical trials and osteoporosis treatment | ECTS2016

Efficacy of odanacatib in postmenopausal women with osteoporosis: subgroup analyses of data from the phase 3 long-term odanacatib fracture trial (LOFT)

Saag Kenneth G , Alexandersen Peter , Benhamou Claude-Laurent , Gilchrist Nigel , Halse Johan , Michael Lewiecki E. , Lippuner Kurt , McClung Michael , Shiraki Masataka , DaSilva Carolyn A , Verbruggen Nadia , Scott Boyd B , Lombardi Antonio

Odanacatib (ODN), a selective oral inhibitor of cathepsin K, is in development for the treatment of osteoporosis. In the primary efficacy analysis of the Phase 3, Long-Term ODN Fracture Trial (LOFT; NCT00529373), ODN significantly reduced fracture risk compared with placebo in postmenopausal women with osteoporosis. Pre-specified subgroup analyses evaluated the efficacy of ODN in patient subgroups.Women aged ≥65 years, without baseline radiographic...

ba0005oc1.2 | Clinical trials and osteoporosis treatment | ECTS2016

Acute effects of calcium supplements on blood pressure: results of a randomised cross-over trial

Bristow Sarah , Billington Emma , Gamble Greg , de Kwant Jordyn , Stewart Angela , Horne Anne , Reid Ian

Calcium supplements are associated with increased cardiovascular risk, but the mechanism by which this occurs is presently uncertain. In a secondary analysis of a trial examining the acute effects of calcium supplements, we found that blood pressure declined over 8 h in the control group, consistent with its diurnal rhythm, and that this decline was smaller in the calcium group [1]. To investigate these effects further, we carried out a randomised controlled cross-over trial o...

ba0005oc1.3 | Clinical trials and osteoporosis treatment | ECTS2016

Treatment with vitamin MK-7 prevents deterioration of trabecular bone

Roenn Sofie Hertz , Harsloef Torben , Pedersen Steen Boenloekke , Langdahl Bente Lomholt

Background: Clinical studies suggest that vitamin K2 prevents bone loss and may protect against fractures. Vitamin K is a cofactor in the carboxylation of Osteocalcin (OC). Carboxylated OC promotes mineralization of bone. The aim of the study was to investigate the effect of vitamin K2 on osteocalcin, bone mass and -quality.Methods: We conducted a randomized placebo-controlled double-blinded clinical trial, in which 142 postmenopausal osteopenic women we...

ba0005oc1.4 | Clinical trials and osteoporosis treatment | ECTS2016

Relationship between total hip (TH) BMD T-score and incidence of nonvertebral fracture (NVFX) with up to 10 years of Denosumab (Dmab) treatment

Ferrari S , Adami S , Brown J P , Cosman F , Czerwiński E , de Gregorio L H , Malouf J , Reginster J-Y , Daizadeh N S , Wang A , Wagman R B , Lewiecki E M

The relationship between BMD T-score and FX risk has not been established in patients receiving osteoporosis therapy. In the FREEDOM Extension study, continuous DMAb therapy for up to 10 years increased BMD levels with no therapeutic plateau at lumbar spine or TH [Bone et al, ASBMR 2015]. Such improvements would only be meaningful if associated with FX reductions. We investigated the relationship between TH BMD T-score and NVFX in women who received DMAb during FREEDOM and tho...

ba0005oc1.5 | Clinical trials and osteoporosis treatment | ECTS2016

Secular trends in prescription incidence of different anti-osteoporotic drugs in the UK population aged 50 years or above from 1990 till 2012

van der Velde Robert , Wyers Caroline , Geusens Piet , van den Bergh Joop , de Vries Frank , Cooper Cyrus , vandeStaa Tjeerd-Pieter , Harvey Nicholas

Objective: To study the trends in prescription of different anti-osteoporotic drugs (AOD) in the UK population aged 50 years or above from 1990 till 2012.Methods: Retrospective observational study using the CPRD data link representative for the total UK population. The incidence of prescription of a specific AOD was calculated by dividing the number of prescriptions by the total person-years (py) of follow-up.Results: AOD prescript...

ba0005oc1.6 | Clinical trials and osteoporosis treatment | ECTS2016

Standard QCT shows substantial underestimation of treatment effects on bone mineral density: impact of spatial resolution

Reinhold Stefan , Damm Timo , Pena Jaime , Barkmann Reinhard , Gluer Claus-C

Quantitative Computed Tomography (QCT) can be performed with different protocols. We investigated whether selection of spatial resolution, reconstruction method, and scanner type have an impact on measured treatment effects for different bone compartments.Methods: In a multi-center study, a group of 50 men, age 55.1 (range 25–78) undergoing 18 months of either osteoanabolic (n=25) or antiresorptive treatment (n=25) were scanned wit...